Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by StockNews.com to Hold

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a research report released on Thursday morning.

Separately, HC Wainwright reaffirmed a neutral rating on shares of Aclaris Therapeutics in a report on Monday. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of Hold and an average price target of $22.25.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $1.35 on Thursday. Aclaris Therapeutics has a one year low of $0.59 and a one year high of $10.15. The company has a market cap of $96.20 million, a PE ratio of -1.24 and a beta of 0.27. The business has a 50-day simple moving average of $1.18 and a 200-day simple moving average of $1.20.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. The business had revenue of $2.40 million during the quarter, compared to the consensus estimate of $1.99 million. On average, sell-side analysts predict that Aclaris Therapeutics will post -0.77 earnings per share for the current fiscal year.

Insider Buying and Selling at Aclaris Therapeutics

In related news, major shareholder Braden Michael Leonard purchased 1,000,000 shares of the company’s stock in a transaction on Tuesday, June 11th. The shares were bought at an average cost of $1.08 per share, for a total transaction of $1,080,000.00. Following the completion of the purchase, the insider now directly owns 10,395,934 shares of the company’s stock, valued at approximately $11,227,608.72. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased 2,435,393 shares of company stock worth $2,750,797 over the last three months. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Aclaris Therapeutics

Large investors have recently modified their holdings of the company. BML Capital Management LLC acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $686,000. Vanguard Group Inc. boosted its holdings in shares of Aclaris Therapeutics by 1.0% in the third quarter. Vanguard Group Inc. now owns 3,363,046 shares of the biotechnology company’s stock valued at $23,037,000 after acquiring an additional 33,482 shares during the period. Monaco Asset Management SAM acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $1,028,000. Octagon Capital Advisors LP acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $105,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Aclaris Therapeutics by 115.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 23,467 shares during the period. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.